Tech Transfer Roundup: Santhera Exits Congenital Muscular Dystrophy Pact To Focus On DMD
Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.
You may also be interested in...
The start-up is built around four business units – technology, manufacturing, R&D and therapeutics – based on internal and external expertise. Kriya will take its first gene therapies into the clinic in 2023.
A mix of equity and debt financing has raised enough to satisfy Santhera's liquidity needs until mid-2022, which will be after the Swiss firm has filed its Duchenne drug vamorolone.
Active Biotech and Ipsen have dropped development of the immunotherapy candidate tasquinimod in prostate cancer after its "unambiguous" failure in a Phase III trial.